These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27810861)

  • 1. Ribociclib Lengthens Breast Cancer Survival.
    Cancer Discov; 2016 Dec; 6(12):1299. PubMed ID: 27810861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
    Sonke GS; Hart LL; Campone M; Erdkamp F; Janni W; Verma S; Villanueva C; Jakobsen E; Alba E; Wist E; Favret AM; Bachelot T; Hegg R; Wheatley-Price P; Souami F; Sutradhar S; Miller M; Germa C; Burris HA
    Breast Cancer Res Treat; 2018 Feb; 167(3):659-669. PubMed ID: 29058175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
    Curigliano G; Gómez Pardo P; Meric-Bernstam F; Conte P; Lolkema MP; Beck JT; Bardia A; Martínez García M; Penault-Llorca F; Dhuria S; Tang Z; Solovieff N; Miller M; Di Tomaso E; Hurvitz SA
    Breast; 2016 Aug; 28():191-8. PubMed ID: 27336726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
    Shah A; Bloomquist E; Tang S; Fu W; Bi Y; Liu Q; Yu J; Zhao P; Palmby TR; Goldberg KB; Chang CJG; Patel P; Alebachew E; Tilley A; Pierce WF; Ibrahim A; Blumenthal GM; Sridhara R; Beaver JA; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(13):2999-3004. PubMed ID: 29437768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
    Hortobagyi GN
    Breast Cancer Res; 2018 Oct; 20(1):123. PubMed ID: 30340505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abemaciclib Shows Promise for Early Breast Cancer.
    Cancer Discov; 2017 Feb; 7(2):119-120. PubMed ID: 27986713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
    Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
    Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
    O'Shaughnessy J; Petrakova K; Sonke GS; Conte P; Arteaga CL; Cameron DA; Hart LL; Villanueva C; Jakobsen E; Beck JT; Lindquist D; Souami F; Mondal S; Germa C; Hortobagyi GN
    Breast Cancer Res Treat; 2018 Feb; 168(1):127-134. PubMed ID: 29164421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Burris HA
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
    Freedman RA; Tolaney SM
    Breast Cancer Res Treat; 2018 Feb; 167(3):607-614. PubMed ID: 29103175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    López-Tarruella S; Jerez Y; Márquez-Rodas I; Echavarria I; Martin M
    Future Oncol; 2017 Oct; 13(24):2137-2149. PubMed ID: 28758424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribociclib in HR-positive, HER2-negative breast cancer.
    Burki TK
    Lancet Oncol; 2016 Nov; 17(11):e482. PubMed ID: 27746106
    [No Abstract]   [Full Text] [Related]  

  • 14. MONALEESA clinical program: a review of ribociclib use in different clinical settings.
    Yardley DA
    Future Oncol; 2019 Aug; 15(23):2673-2686. PubMed ID: 31305131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
    Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
    Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Zangardi ML; Spring LM; Blouin GC; Bardia A
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1169-1176. PubMed ID: 28875723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
    Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
    Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribociclib: First Global Approval.
    Syed YY
    Drugs; 2017 May; 77(7):799-807. PubMed ID: 28417244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
    Yardley DA; Hart L; Favret A; Blau S; Diab S; Richards D; Sparano J; Beck JT; Richards P; Ward P; Ramaswamy B; Tsai M; Blackwell K; Pluard T; Tolaney SM; Esteva FJ; Truica CI; Alemany C; Volas-Redd G; Shtivelband M; Purkayastha D; Dalal AA; Miller M; Hortobagyi GN
    Clin Breast Cancer; 2019 Aug; 19(4):268-277.e1. PubMed ID: 31160171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.